• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Everest Organics develops remdesivir API

expresspharmaAugust 11, 2020

Tag: Everest Organics , Remdesivir , API

Everest Organics has announced that it has successfully developed remdesivir API has been in its R&D facility.

Dr Sirisha Srikakarlapudi, Director, EOL – New Product Development said, “lt’s a moment of utmost satisfaction that with hard work of the past few months by Everest Organics R&D team, we have been able to successfully develop remdesivir API at lab scale in a short span of time. In fact, we are poised for the development of more products in the anti-viral segments in the future.”


Previous:IIT Mandi team compares disordered proteins in COVID-19 virus through computational studies

Next:VAV Lipids gets written confirmation from CDSCO for Ratnagiri facility

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Everest Organics develops remdesivir API | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Clozapine EP Impurity D

Clozapine EP Impurity D
Ethynyl estradiol USP Hormone API made in china

Ethynyl estradiol USP Hormone API made in china
APIXABAN

APIXABAN
Capillary Wormwood Extract

Capillary Wormwood Extract
Sulfalen CP supplier API Pharmaceutical Sulfanilamide made in china

Sulfalen CP supplier API Pharmaceutical Sulfanilamide made in china
Isavuconazole API

Isavuconazole API
Apitolisib(GDC-0980)

Apitolisib(GDC-0980)
Cefatrizine propylene glycol JP 98%min supplier Pharmaceutical API Antibiotics made in china

Cefatrizine propylene glycol JP 98%min supplier Pharmaceutical API Antibiotics made in china
Labconco RapidVap Vertex Dry Evaporator

Labconco RapidVap Vertex Dry Evaporator
Pharmaceutical Grade API Desloratadine CAS 100643-71-8

Pharmaceutical Grade API Desloratadine CAS 100643-71-8

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service